ClinicalTrials.gg
CompletedNCT02947347Updated Mar 17, 2026Results posted

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

A Phase 3 interventional study of Ibrutinib Oral Capsule and Placebo in Follicular Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 128 sites in 19 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ibrutinib in Lymphoma, Follicular — none open to participants now, 7 under way, 1 of them phase 3. ibrutinib · Lymphoma, Follicular.

Enrollment
2nd of 24
445 · median 48
Started
2017
with 2 others
Phase 3
4 of 24
none open now
Registered
17th of 24
by date
Lead sponsor
4 of 24
Pharmacyclics LLC.

Among the 24 studies testing ibrutinib in Lymphoma, Follicular, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 3, and was the 17th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 24 studies testing ibrutinib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing ibrutinib in Lymphoma, Follicular as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • PCYC
  • Pharmacyclics
  • ibrutinib
  • rituximab
  • FL
  • Non-Hodgkin's Lymphoma
  • NHL
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.
  • Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.
  • Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
  • Adequate hematologic function within protocol-defined parameters.
  • Adequate hepatic and renal function within protocol-defined parameters.
  • performance status score of 0-2.

Exclusion criteria

Exclusion Criteria:

  • Transformed lymphoma
  • Prior treatment for follicular lymphoma.
  • Central nervous system lymphoma or .
  • Currently active, cardiovascular disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
445 participants (actual)

Study arms

  • Experimental
    (Arm A) ibrutinib + rituximab

    Participants to receive 560mg of ibrutinib once daily and rituximab 375mg/m\^2 weekly x4 with maintenance.

    Drug: Ibrutinib Oral Capsule · Drug: Rituximab

  • Placebo comparator
    (Arm B) placebo + rituximab

    Participants to receive placebo once daily and rituximab 375mg/m\^2 weekly x4 with maintenance.

    Drug: Placebo · Drug: Rituximab

Interventions

  • Ibrutinib 560mg administered orally daily

    Also known as: Imbruvica

  • DrugPlacebo

    Placebo capsules to match ibrutinib administered orally daily

  • Rituximab 375mg/m\^2 intravenously (IV) weekly

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by Investigator

    PFS is the time from the date of randomization to the date of the first documented evidence of disease progression (based on the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014, Lugano Classification\]) or death from any cause, whichever occurs first. Participants who initiated subsequent anticancer therapy or missed two or more consecutive overall disease assessments were censored as described in the SAP. Estimated by Kaplan-Meier method.

    Time frame: Primary Analysis cut-off; median overall follow-up of 53.75 months

Secondary outcomes

  1. Overall Response Rate (ORR) as Assessed by Investigator

    ORR is the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) as determined by the investigator according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014, Lugano Classification). ORR was assessed from the date of randomization through the date of first documented disease progression or initiation of subsequent anti-cancer therapy, whichever occurred first. Participants who did not have any post-baseline disease assessments or who initiated subsequent anti-cancer therapy prior to a documented response are considered non-responders.

    Time frame: Primary Analysis; median overall follow-up of 53.75 months

  2. Overall Survival (OS)

    Overall survival is defined as the interval between the date of randomization and the date of the participant's death from any cause. If a participant is not known to have died (this includes participants with unknown death date), OS will be censored at the date the participant was last known to have been alive. Estimated by Kaplan-Meier method.

    Time frame: Final Analysis; median overall follow-up of 58.97 months

  3. Infusion-related Reaction Rate Assessed by Investigator

    The infusion-related reactions (IRR) rate is the proportion of subjects experiencing infusion related reactions that start on the day of a rituximab infusion and are assessed as related or possibly related to rituximab.

    Time frame: Primary Analysis; median overall follow-up of 53.75 months

  4. Duration of Response (DOR) as Assessed by Investigator

    DOR is defined as the time from initial complete response (CR) or partial response (PR) to progressive disease (PD) or death due to any cause, whichever is first reported, regardless of discontinuation of study treatment. If such event did not occur, then participants were to be censored at the last adequate disease assessment as required for PFS censoring. Estimated by Kaplan-Meier method.

    Time frame: Primary Analysis; median overall follow-up of 53.75 months

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The treatment-emergent period is defined as the period from the date of the first dose of study treatment up to 30 days after the date of the last dose of study treatment or the day before initiation of subsequent anti-cancer therapy, whichever comes first. The treatment-emergent adverse events (TEAEs) are those events that occur or worsen during the treatment-emergent period or that are related to the study treatment.

    Time frame: Overall median treatment duration of 22.11 months

07

Results

Posted Mar 17, 2026

Participant flow

In total, 445 participants were enrolled at 128 sites in 19 countries. Participants were randomly assigned in a 3:1 ratio to the Ibrutinib + Rituximab arm (Arm A; n=334) or the Placebo + Rituximab arm (Arm B; n=111). Randomization was stratified on the basis of: (a) age (60-69 vs. ≥70 years), (b) Follicular Lymphoma-specific International Prognostic Index (FLIPI)-1 score (low vs. intermediate/high) and (c) ECOG performance status score (0/1 vs. 2).

Participant flow — Overall Study
MilestoneArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Started334111
On study treatment at study closure5022
Off treatment and on follow-up at study closure10833
Completed15855
Not completed17656
Withdrew: Death10935
Withdrew: Lost to follow-up74
Withdrew: Withdrawal of consent5014
Withdrew: Other103

Outcome measures

PrimaryProgression-Free Survival (PFS) as Assessed by Investigator

PFS is the time from the date of randomization to the date of the first documented evidence of disease progression (based on the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014, Lugano Classification\]) or death from any cause, whichever occurs first. Participants who initiated subsequent anticancer therapy or missed two or more consecutive overall disease assessments were censored as described in the SAP. Estimated by Kaplan-Meier method.

Time frame:
Primary Analysis cut-off; median overall follow-up of 53.75 months
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by Investigator
monthsArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Progression-Free Survival (PFS) as Assessed by Investigator42.02 (33.31 to 50.83)32.76 (22.05 to 38.67)
Statistical analysis
  • Arm A: Ibrutinib + Rituximab vs Arm B: Placebo + Rituximab · Log Rank · p = 0.0231 · Hazard ratio (hr): 0.713 · 95% CI 0.532 to 0.955
SecondaryOverall Response Rate (ORR) as Assessed by Investigator

ORR is the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) as determined by the investigator according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014, Lugano Classification). ORR was assessed from the date of randomization through the date of first documented disease progression or initiation of subsequent anti-cancer therapy, whichever occurred first. Participants who did not have any post-baseline disease assessments or who initiated subsequent anti-cancer therapy prior to a documented response are considered non-responders.

Time frame:
Primary Analysis; median overall follow-up of 53.75 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by Investigator
percentage of participantsArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Overall Response Rate (ORR) as Assessed by Investigator81.4 (76.8 to 85.5)68.5 (59.0 to 77.0)
Statistical analysis
  • Arm A: Ibrutinib + Rituximab vs Arm B: Placebo + Rituximab · Cochran-Mantel-Haenszel · p = 0.0040 (Adjustment based on FLIPI-1 and ECOG at randomization combined into a 3 strata variable: FLIPI-1 score=low; FLIPI-1 score=intermediate/high and ECOG performance status score=0/1; FLIPI-1 score=intermediate/high and ECOG performance status score=2.) · Response rate ratio: 1.190 · 95% CI 1.039 to 1.364
SecondaryOverall Survival (OS)

Overall survival is defined as the interval between the date of randomization and the date of the participant's death from any cause. If a participant is not known to have died (this includes participants with unknown death date), OS will be censored at the date the participant was last known to have been alive. Estimated by Kaplan-Meier method.

Time frame:
Final Analysis; median overall follow-up of 58.97 months
Reported as:
Median · months
Overall Survival (OS)
monthsArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Overall Survival (OS)NA (69.72 to NA)78.98 (57.36 to NA)
Statistical analysis
  • Arm A: Ibrutinib + Rituximab vs Arm B: Placebo + Rituximab · Log Rank · p = 0.6608 · Hazard ratio (hr): 1.083 · 95% CI 0.758 to 1.548Hazard ratio is estimated using stratified Cox regression model.
SecondaryInfusion-related Reaction Rate Assessed by Investigator

The infusion-related reactions (IRR) rate is the proportion of subjects experiencing infusion related reactions that start on the day of a rituximab infusion and are assessed as related or possibly related to rituximab.

Time frame:
Primary Analysis; median overall follow-up of 53.75 months
Reported as:
Number · percentage of participants
Infusion-related Reaction Rate Assessed by Investigator
percentage of participantsArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Infusion-related Reaction Rate Assessed by Investigator21.3 (17.0 to 26.0)27.0 (19.0 to 36.3)
Statistical analysis
  • Arm A: Ibrutinib + Rituximab vs Arm B: Placebo + Rituximab · Chi-squared · p = 0.2087 (P-value for rate ratio is based on Chi-Square test.) · Rate ratio: 0.787 · 95% CI 0.544 to 1.137For rate ratio, numerator is Ibrutinib + Rituximab arm (Arm A) and denominator is Placebo + Rituximab arm (Arm B). Confidence interval based on Wald confidence limits.
SecondaryDuration of Response (DOR) as Assessed by Investigator

DOR is defined as the time from initial complete response (CR) or partial response (PR) to progressive disease (PD) or death due to any cause, whichever is first reported, regardless of discontinuation of study treatment. If such event did not occur, then participants were to be censored at the last adequate disease assessment as required for PFS censoring. Estimated by Kaplan-Meier method.

Time frame:
Primary Analysis; median overall follow-up of 53.75 months
Reported as:
Median · months
Duration of Response (DOR) as Assessed by Investigator
monthsArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Duration of Response (DOR) as Assessed by Investigator44.25 (36.63 to NA)34.56 (29.21 to 47.31)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The treatment-emergent period is defined as the period from the date of the first dose of study treatment up to 30 days after the date of the last dose of study treatment or the day before initiation of subsequent anti-cancer therapy, whichever comes first. The treatment-emergent adverse events (TEAEs) are those events that occur or worsen during the treatment-emergent period or that are related to the study treatment.

Time frame:
Overall median treatment duration of 22.11 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
Any Treatment-Emergent Adverse Event (TEAE)324106
Grade ≥3 TEAEs25963
Serious Adverse Events (SAEs)20445
Fatal TEAEs486
Discontinued study drug due to AE14416
Most frequent Grade ≥3 TEAE (neutropenia)528

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent/enrollment to the end of the study. The median time on follow-up (or mean time participants were followed) was 58.2 months for Arm A (Ibrutinib + Rituximab) and 60.0 months for Arm B (Placebo + Rituximab).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Ibrutinib + Rituximab123/334 (36.8%)214/334 (64.1%)310/334 (92.8%)
Arm B: Placebo + Rituximab40/111 (36%)48/111 (43.2%)101/111 (91%)
Most frequent serious events
Showing 10 of 280
Most frequent serious events
EventArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
PNEUMONIAInfections and infestations36/3345/111
COVID-19Infections and infestations25/3341/111
ATRIAL FIBRILLATIONCardiac disorders21/3342/111
COVID-19 PNEUMONIAInfections and infestations21/3345/111
URINARY TRACT INFECTIONInfections and infestations11/3344/111
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders5/3343/111
DEATHGeneral disorders2/3342/111
GASTROENTERITISInfections and infestations1/3342/111
INFLUENZAInfections and infestations3/3342/111
HUMERUS FRACTUREInjury, poisoning and procedural complications0/3342/111
Most frequent other events
Showing 10 of 61
Most frequent other events
EventArm A: Ibrutinib + RituximabArm B: Placebo + Rituximab
DIARRHOEAGastrointestinal disorders116/33415/111
FATIGUEGeneral disorders72/33416/111
NAUSEAGastrointestinal disorders69/33412/111
NEUTROPENIABlood and lymphatic system disorders67/33412/111
COVID-19Infections and infestations62/33422/111
OEDEMA PERIPHERALGeneral disorders63/33418/111
ARTHRALGIAMusculoskeletal and connective tissue disorders63/33416/111
DYSPNOEARespiratory, thoracic and mediastinal disorders38/33420/111
DRY EYEEye disorders60/33417/111
URINARY TRACT INFECTIONInfections and infestations60/33410/111

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(Years)Arm A: Ibrutinib + RituximabArm B: Placebo + RituximabTotal
Mean73.7 ± 6.3874.2 ± 5.9673.8 ± 6.28
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Ibrutinib + RituximabArm B: Placebo + RituximabTotal
Female18353236
Male15158209
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Ibrutinib + RituximabArm B: Placebo + RituximabTotal
Hispanic or Latino19827
Not Hispanic or Latino304103407
Unknown or Not Reported11011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Ibrutinib + RituximabArm B: Placebo + RituximabTotal
American Indian or Alaska Native011
Asian131023
Native Hawaiian or Other Pacific Islander000
Black or African American202
White30497401
More than one race000
Unknown or Not Reported15318
08

Study locations

128 sites
  • Southern Cancer Center
    Mobile, Alabama 36526, United States
  • City of Hope
    Duarte, California 91010, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • UCLA Hematology/Oncology
    Santa Monica, California 90095, United States
  • Helen F. Graham Cancer Center and Research Institute
    Newark, Delaware 19713, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33916, United States
  • Florida Cancer Affiliates
    Ocala, Florida 34471, United States
  • SCRI Florida Cancer Specialists North
    St. Petersburg, Florida 33709, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Goldschmidt Cancer Center
    Jefferson City, Missouri 65109, United States
  • Southeast Nebraska Cancer Center
    Lincoln, Nebraska 68510, United States
  • OHSU Knight Cancer Institute Beaverton Clinic
    Beaverton, Oregon 97006, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • SCRI Tennessee Oncology Chattanooga
    Chattanooga, Tennessee 37404-1108, United States
  • SCRI Tennessee Oncology Nashville
    Nashville, Tennessee 37203, United States
  • Texas Oncology (Medical City)
    Dallas, Texas 75230, United States
  • Texas Oncology-Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • SCRI The Center For Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology (Tyler)
    Tyler, Texas 75702, United States
  • Oncology and Hematology Associates of Southwest Virginia (Blacksburg)
    Blacksburg, Virginia 24060, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • W VA University Mary Babb Randolph Cancer Center
    Morgantown, West Virginia 26506, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory, Australia
  • Mater Misericordiae Health Services
    South Brisbane, Queensland, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania, Australia
  • Monash Medical Centre Clayton Campus
    Clayton, Victoria, Australia
  • Andrew Love Cancer Center
    Geelong, Victoria, Australia
  • Universitätsklinikum Innsbruck
    Innsbruck, Tyrol, Austria
  • Uniklinikum Salzburg
    Salzburg, Austria
  • Cliniques Universitaires Saint-Luc
    Brussels, Brussels Capital, Belgium
  • ZNA Stuivenberg
    Antwerp, Belgium
  • AZ Sint-Jan Brugge Oostende AV
    Bruges, Belgium
  • UZ Gent
    Ghent, Belgium
  • CHU de Liège
    Liège, Belgium
  • AZ Nikolaas
    Sint-Niklaas, Belgium
  • Gasthuis Zusters Antwerpen
    Wilrijk, Belgium
  • Moncton Hospital
    Moncton, New Brunswick, Canada
  • CHUM Notre Dame Hospital
    Montreal, Quebec, Canada
  • CIUSSS-de-l'Est-de-l'Île-de-Montréal
    Montreal, Quebec, Canada
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, Czechia
  • Fakultni nemocnice v Motole
    Prague, Czechia
  • Centre Hospitalier de Valence
    Valence, Drôme, France
  • CHRU de Poitiers La Miletrie
    Poitiers, Vienne, France
  • CHU de Limoges Hôpital Dupuytren
    Limoges, France
  • CHU Bordeaux
    Pessac, France
  • Centre Hospitalier de Perigueux
    Périgueux, 24019, France
  • Hôpital Civil
    Strasbourg, France
  • University General Hospital of Patras
    Pátrai, Achaïa, Greece
  • Laiko General Hospital of Athens
    Athens, Attica, Greece
  • University General Hospital of Larissa
    Larissa, Greece
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, Somogy County 7400, Hungary
  • Országos Onkológiai Intézet
    Budapest, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hungary
  • Petz Aladár Megyei Oktató Kórház
    Győr, Hungary
  • Pécsi Tudományegyetem
    Pécs, Hungary
  • Barzilai Medical Center
    Ashkelon, Israel
  • Bnei Zion Medical Center
    Haifa, Israel
  • Lady Davis Carmel Medical Center
    Haifa, Israel
  • Rabin Medical Center Beilinson Campus
    Petah Tikva, Israel
  • Assuta Medical Center
    Tel Aviv, Israel
  • Assaf Harofe Medical Center
    Ẕerifin, Israel
  • Ospedale Infermi di Rimini
    Rimini, Emilia-Romagna, Italy
  • Ospedale Policlinico San Martino
    Genoa, Liguria, Italy
  • Istituto Europeo Di Oncologia
    Milan, Lombardy, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Turin, Piedmont, Italy
  • Azienda ospedaliera Universiataria Senese
    Siena, Tuscany, Italy
  • Centro Di Riferimento Oncologico
    Aviano, Italy
  • Azienda Sanitaria Ospedaliera S. Croce e Carle
    Cuneo, 12100, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST
    Meldola, 47014, Italy
  • San Raffaele Scientific Institute
    Milan, Italy
  • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
    Milan, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, Italy
  • Farmacia Polo Ematologico Policlinico Umberto I
    Roma, Italy
  • Policlinico Universitario Campus Biomedico di Roma
    Roma, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, Italy
  • Gelre Ziekenhuizen
    Apeldoorn, Gelderland, Netherlands
  • Maasstad Ziekenhuis
    Rotterdam, South Holland, Netherlands
  • Leids Universitair Medisch Centrum
    Leiden, Netherlands
  • ETZ-Elisabeth
    Tilburg, Netherlands
  • Centrum Onkologii Ziemi Lubelskiej
    Lublin, Lublin Voivodeship, Poland
  • Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii
    Gdansk, Pomeranian Voivodeship, Poland
  • Szpitale Pomorskie Sp. z o. o.
    Gdynia, Pomeranian Voivodeship, Poland
  • Malopolskie Centrum Medyczne
    Krakow, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu
    Wroclaw, Poland
  • Unidade Local de Saúde de Matosinhos SA
    Matosinhos Municipality, Portugal
  • Centro Hospitalar de São João, E.P.E.
    Porto, 4200-319, Portugal
  • Centro Hospitalar do Porto - Hospital de Santo António
    Porto, Portugal
  • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
    Porto, Portugal
  • Regional Clinical Hospital
    Krasnoyarsk, Russia
  • Russian Oncology Research Center n a N N Blokhin
    Moscow, Russia
  • Nizhegorodskaya Regional Clinical Hospital n.a. Semashko
    Nizhny Novgorod, Russia
  • City Hospital #31
    Saint Petersburg, Russia
  • North-West Federal Medical Research Center n.a. V.A. Almazov
    Saint Petersburg, Russia
  • Hospital de Cabueñes
    Gijón, Principality of Asturias, Spain
  • Hospital Universitario Virgen de Valme
    Seville, Sevilla, Spain

Showing the first 100 of 128 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Belada D, Gardner FP, de Oliveira AC, Sancho JM, Lomaia E, Wright D, Turgut M, Martynova E, Lazar Z, Anz B, Wang MC, Legiec W, Opat S, Pailden J, Peltier HM, Marturano E, Dean JP, Flinn IW. Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. Hemasphere. 2026 Jun 17;10(6):e70400. doi: 10.1002/hem3.70400. eCollection 2026 Jun. PubMed 42317205 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2024, 84 months.

Results were first posted in Mar 2026, 2 years after primary completion. A results delay was requested in Jan 2025.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's 84 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Oct 27, 2016
StartActual
Jan 23, 2017
Primary completionActual
Feb 21, 2024
CompletionActual
Jun 9, 2025
Results delay requested
Jan 21, 2025
Results first posted
Mar 17, 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02947347
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Oct 27, 2016
Start date
Jan 23, 2017
Primary completion
Feb 21, 2024
Completion
Jun 9, 2025
Results posted
Mar 17, 2026
Last update
Mar 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion